<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transplant</journal-id><journal-id journal-id-type="publisher-id">JTRAN</journal-id><journal-title-group><journal-title>Journal of Transplantation</journal-title></journal-title-group><issn pub-type="ppub">2090-0007</issn><issn pub-type="epub">2090-0015</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1155/2009/436515</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Chemokine Receptor-5&#x00394;32 Mutation is No Risk Factor for Ischemic-Type Biliary Lesion in Liver Transplantation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Heidenhain</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Puhl</surname><given-names>Gero</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Moench</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lautem</surname><given-names>Anja</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Neuhaus</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of General, Visceral and Transplantation Surgery, Charit&#x000e9;-University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany</aff><aff id="I2"><sup>2</sup>Department of General and Visceral Surgery, J.W. Goethe University Frankfurt/Main, Theodor Stern Kai 7, 60590 Frankfurt/Main, Germany</aff><aff id="I3"><sup>3</sup>Department of Transplantation Surgery, Johannes Gutenberg University of Mainz, Langenbeckstra&#x000df;e 1, 55131 Mainz, Germany</aff><author-notes><corresp id="cor1">*Christoph Heidenhain: <email>christoph.heidenhain@charite.de</email></corresp><fn fn-type="other"><p>Recommended by Carlos Esquivel</p></fn></author-notes><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>30</day><month>3</month><year>2009</year></pub-date><volume>2009</volume><elocation-id>436515</elocation-id><history><date date-type="received"><day>20</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>23</day><month>2</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Christoph Heidenhain et al.</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>It has been shown that certain chemokine receptor polymorphisms may correspond to certain complications after organ transplantation. Ischemic-type biliary lesion (ITBL) encounters for major morbidity and mortality in liver transplant recipients. So far, the exact cause for ITBL remains unclear. Certain risk factors for the development of ITBL like donor age and cold ischemic time are well described. In a previous study, a 32-nucleotide deletion of the chemokine receptor-5&#x00394;32 (CCR-5&#x00394;32) was strongly associated with the incidence of ITBL in adult liver transplantation. This study re-evaluates the association of CCR-5&#x00394;32 gene polymorphism and the incidence of ITBL. 169 patients were included into this retrospective analysis. 134 patients were homozygous for wild-type CCR-5, 33 patients heterozygous, and 2 patients were homozygous for CCR-5&#x00394;32 mutation. There were no major differences in donor or recipients demographics. No association was found between CCR-5&#x00394;32 mutation and the development of ITBL. We conclude that CCR-5&#x00394;32 is no risk factor for the development of ITBL in our patient cohort.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. Introduction</title><p>The terms &#x0201c;nonanastomotic biliary strictures&#x0201d;, &#x0201c;intrahepatic biliary strictures&#x0201d;, or &#x0201c;ischemic-type biliary lesion&#x0201d; (ITBL) are often used as synonyms for hilar or intrahepatic diffuse bile duct strictures, necrosis, ecstasies, or dilatations (see <xref ref-type="fig" rid="fig1">Figure 1</xref>) [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. The reported incidence of ITBL after OLT varies between 1.4% and 20% [<xref ref-type="bibr" rid="B3">3</xref>&#x02013;<xref ref-type="bibr" rid="B5">5</xref>]. Some centers report even higher incidence [<xref ref-type="bibr" rid="B6">6</xref>]. Patient and graft survival after the diagnosis of ITBL are significantly reduced [<xref ref-type="bibr" rid="B7">7</xref>]. ITBL is the third most common reason for hepatic retransplantation [<xref ref-type="bibr" rid="B8">8</xref>]. This complication encounters for major morbidity and mortality, creates high costs, and aggravates organ shortage [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>].</p><p>The exact cause of ITBL still remains unclear. Only relevant risk factors are described. However, data about risk factors for the development of ITBL are inconsistent. A recent study on 1113 liver transplant patients showed no relevant donor or recipient risk factor of ITBL [<xref ref-type="bibr" rid="B5">5</xref>]. There are only two studies evaluating the impact of chemokine receptors (CCR) on the development of ITBL [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B9">9</xref>]. In Moench's study on 146 OLT patients CCR-5&#x00394;32 mutation was evaluated and correlated with a significant increased incidence of ITBL [<xref ref-type="bibr" rid="B6">6</xref>]. A recent study on 137 pediatric liver transplants failed to show an association between CCR-5&#x00394;32 and biliary complications [<xref ref-type="bibr" rid="B9">9</xref>]. CCR-5&#x00394;32 is a single base-pair deletion of CCR-5 that leads to a nonfunctional receptor [<xref ref-type="bibr" rid="B10">10</xref>]. The clinical impact of this mutation was first described for homozygous CCR-5&#x00394;32 Caucasians being highly resistant to HIV-1 infection [<xref ref-type="bibr" rid="B11">11</xref>]. If there was an immunological cause for ITBL, a nonfunctional CCR might be relevant for this complication. Homozygous CCR-5&#x00394;32 patients showed a significant increased renal allograft survival [<xref ref-type="bibr" rid="B12">12</xref>]. Experimental studies correlated a nonfunctional CCR-5 with less acute rejection episodes in lung [<xref ref-type="bibr" rid="B13">13</xref>], heart [<xref ref-type="bibr" rid="B14">14</xref>] and islet cell transplantation [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>The aim of this study was to re-examine a correlation of CCR-5&#x00394;32 genotype with the susceptibility of ITBL within our patients.</p></sec><sec sec-type="section" id="sec2"><title>2. Patients and Methods</title><p>169 liver transplant patients were analyzed retrospectively. All patients were transplanted at the transplant center of the Humboldt University of Berlin between 03/2002 and 03/2005 and were included during routine Follow-up examination. Follow-up period was 24 months minimum. 11 patients with the established diagnosis of ITBL, that were transplanted earlier than 03/2001, were selectively included into this study due to the low incidence of ITBL of only 4.0% within our patients. The diagnosis of ITBL was made within the first year after transplantation in 82% of the patients. The following demographic data were extracted from the hospital records and evaluated: age, gender, underlying liver disease, blood group, Child-Pugh score (CPS), model for end stage liver disease score (MELD score), initial immunosuppression, cytomegalovirus infection (CMV), HLA match, donor age and gender, donor serum sodium, cause of brain death and length of stay on intensive care unit (ICU) prior to organ harvesting. 154 patients received a cadaver graft, 15 patients received a graft from a living donor. Altogether, 19 split-liver transplantation were included. The local ethic committee approved the study. Written informed consent was obtained from all patients before blood was taken for DNA analysis.</p></sec><sec sec-type="section" id="sec3"><title>3. Definition of ITBL</title><p>ITBL was defined as nonanastomotic intra- or extrahepatic biliary strictures without any history of hepatic artery complications, ABO, incompatibility or other known causes of bile duct damages. In all cases patency of the hepatic artery was proved by Doppler ultrasound, computer tomography based angiography or conventional angiography. Recurrence of primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC) and vanishing bile duct syndrome were ruled out in all cases by liver biopsy. Diagnosis of ITBL was always established with endoscopic retrograde cholangiography or percutaneous transhepatic cholangiography.</p></sec><sec sec-type="section" id="sec4"><title>4. Genotype Analysis</title><p>All genotype analyses were performed at the Johannes Gutenberg University of Mainz, Department of Transplantation Surgery. For analysis of the CCR-5 genotype, genomic DNA was prepared from 200 <italic>&#x003bc;</italic>L peripheral blood using the QIAamp DNA blood kit (Qiagen, Cologne, Germany). 2.5 <italic>&#x003bc;</italic>L of DNA were amplified by PCR using the following CCR-5 specific primers: CCR-sense, 5&#x02032;-CAAAAAGAAGGTCTTCATTACACC-3&#x02032; and CCR-5-antisense, 5&#x02032;-CCTGTGCCTCTTCTTCTCATTTCG-3&#x02032;. The PCR mixture was composed of 2.5 <italic>&#x003bc;</italic>L 10 x PCR buffer (Roche Molecular Systems, Mannheim, Germany), 0.5 <italic>&#x003bc;</italic>L of 12.5 mmol/L dNTP (PeqLab, Erlangen, Germany), 2.5 <italic>&#x003bc;</italic>L of each sense and antisense primer (10 <italic>&#x003bc;</italic>mol/L), and 1.25 U AmpliTag DNA polymerase (Roche Molecular Systems) in a total volume of 25 <italic>&#x003bc;</italic>L. Forty PCR cycles were run on a Genius thermocycler (Techne, Cambridge, UK), using the following temperature profile: initial denaturation, 94&#x000b0;C 3 minutes; amplification, 94&#x000b0;C 1 minute, 64&#x000b0;C 1 minute, and, 72&#x000b0;C 1 minute (40 cycles); terminal elongation, 72&#x000b0;C 9 minutes. The size of the wild-type product was 189 base pairs (bp), and the CCR-5&#x00394;32 allele yielded a product of 157 bp. PCR products were analyzed by 2% agarose gel electrophoresis.</p></sec><sec sec-type="section" id="sec5"><title>5. Statistical Analysis</title><p>All statistical calculations were performed in SPSS 11.3 (SPSS Inc., Chicago, USA). Data are given as mean values &#x000b1; standard deviation. Descriptive statistics were used to summarize the donor and recipients characteristics. For independent variables, cross tabulations and chi-square tests were performed. Nonparametric variables were evaluated with Fisher's exact test, and asymptotic significance was calculated.</p><p>All of the tests performed were two-sided. <italic>P</italic>-values of <italic>P</italic> &#x0003c; .05 were considered as statistically significant. All calculations were performed in association with the Department of Biometrical Medicine of the Humboldt University of Berlin.</p></sec><sec sec-type="section" id="sec6"><title>6. Results</title><sec sec-type="subsection" id="subsec6.1"><title>6.1. Patient Characteristics and Genotype Distribution</title><p>A total number of 169 liver transplant recipients were available for genotyping and complete data analysis. Gender and age were equally distributed between wild-type group (wt/wt) and heterozygous CCR-5&#x00394;32 group (wt/&#x00394;32). Patients in the homozygous group (&#x00394;32/&#x00394;32) were female and male. The observed genotype frequency was as expected assessed by Hardy-Weinberg equilibrium in the study population. There were no differences between wt/wt group and wt/&#x00394;32 group regarding to CPS score, MELD score or blood group (<xref ref-type="table" rid="tab1">Table 1</xref>).</p><p>There were no statistical significant differences in the composition of underlying liver disease of group wt/wt and wt/&#x00394;32. Both patients with &#x00394;32/&#x00394;32 had primary biliary cirrhosis as underlying liver disease.</p><p>Initial immunosuppression was tacrolimus based in 82.6% in the wt/wt group compared to 84.8% in the wt/&#x00394;32 group. Likewise, cold ischemic time and HLA match showed no differences between groups. Both homozygous &#x00394;32 patients had zero HLA match. CMV infection that demanded ganciclovir treatment was present in approximately 30% in the wt/wt and wt/&#x00394;32 group and in both homozygous patients.</p></sec><sec sec-type="subsection" id="subsec6.2"><title>6.2. Donor Characteristics</title><p>There were no differences between group regarding donor age or gender. Donors of group &#x00394;32/&#x00394;32 were younger (35.7 years versus 46.5 years and 48.5 years). Mean donor serum sodium was 146.9 mmol/L in the wt/wt group compared with 147.7 mmol/L in the wt/&#x00394;32 group and 155.5 mmol/L in the &#x00394;32/&#x00394;32 group. Data of causes of brain death and length of stay on the ICU prior to organ harvesting are shown in <xref ref-type="table" rid="tab2">Table 2</xref>.</p></sec><sec sec-type="subsection" id="subsec6.3"><title>6.3. Incidence ITBL and Rate of Retransplantation</title><p>Incidence of ITBL was 11.2% in this study due to the selection of patients with ITBL that were additionally included into this evaluation. Homozygous &#x00394;32 patients developed no ITBL compared to 11.2% and 12.1% of homozygous wild-type patients and heterozygous patients, respectively. The rate of retransplantation was 3.0% in both wt/wt and wt/&#x00394;32 group (see <xref ref-type="table" rid="tab3">Table 3</xref>). Retransplantation of the heterozygous patient was indicated due to chronic ductopenic rejection following OLT for PSC. In the wt/wt group, the indications for retransplantation were INF, cryptogenic recirrhosis, and ITBL.</p></sec></sec><sec sec-type="section" id="sec7"><title>7. Discussion</title><p>The problem of genetic association studies and complex clinical syndromes or diseases must be addressed. One can always question the usefulness of these studies that are often even small in sample size. Most of these studies are statistically underpowered. On the other side, it seems important to undertake replication studies for reported associations between genetic polymorphisms and diseases, especially in diseases of major clinical importance.</p><p>In this study, the distribution of heterozygous &#x00394;32 and homozygous &#x00394;32 mutation was very consistent with the published data of the global distribution of this gene polymorphism [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B16">16</xref>]. Heterozygous and homozygous genotypes occur in Caucasian population in 15%&#x02013;20% and 1%, respectively [<xref ref-type="bibr" rid="B16">16</xref>]. Heterozygous individuals show no abnormal receptor function compared with wt/wt individuals. All examined donor and recipient factors showed no statistical differences between groups. This seems important due to the small number of patients included in this study and the possible bias by including selected patients with the diagnosis of ITBL into the study cohort.</p><p>Despite increasing success rates in clinical OLT over the past decades, ITBL remains a major cause for recipient morbidity and mortality [<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B5">5</xref>]. This single complication creates enormous costs and aggravates organ shortage. Up till today, only risk factors for ITBL could be identified in various clinical studies. The length of cold ischemic time was correlated with the development of ITBL [<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B4">4</xref>]. Donor age was found to be a significant risk factor for ITBL. Other studies were not able to show these correlations [<xref ref-type="bibr" rid="B5">5</xref>]. Immunological causes seem to play only a minor role in the pathogenesis of ITBL. Moench et al. described a single base-pair deletion in the coding region of the chemokine receptor-5&#x00394;32, CCR-5&#x00394;32, to be a significant risk factor for the development of ITBL. In Moench's study on 146 OLT patients CCR-5&#x00394;32 was a significant risk factor for ITBL (incidence of ITBL in CCR-5&#x00394;32 patients was 30% versus 11.7% in CCR-5 wild-type patients) and was correlated with a decreased survival rate after OLT. The overall ITBL rate was 15% [<xref ref-type="bibr" rid="B6">6</xref>]. The different incidence of ITBL of the study by Moench and this study may be a reason for the different findings, even though both investigators used the same definition of ITBL. Donors were younger in this study with 38.2 &#x000b1; 16 (non-ITBL patients) and 42.9 &#x000b1; 17 (ITBL) versus 46 &#x000b1; 14 (non-ITBL) and 52 &#x000b1; 14 (ITBL) in Moench's study. However, cold ischemic time was shorter in Moench's investigation (564 minutes (ITBL) and 538 minutes (non-ITBL) versus 637 minutes (ITBL) and 558 minutes (non-ITBL)). The use of arterial back table perfusion was also routinely done for all organs that were harvested by a team of our own. Fischer-Maas et al. analyzed CCR-5&#x00394;32 polymorphism in 137 pediatric patients but showed no correlation with biliary complications [<xref ref-type="bibr" rid="B9">9</xref>]. The incidence of ITBL varies between 1.4% and 20% according to the literature, which might be a problem of different definition of this disease [<xref ref-type="bibr" rid="B3">3</xref>&#x02013;<xref ref-type="bibr" rid="B5">5</xref>]. The rate of ITBL in our OLT patients (2100 patients between 1988 and 2004) is 4.0%. In the presented study on 169 OLT patients the overall incidence of ITBL was 11.7%, but only due to a selective inclusion of patients with the established diagnosis of ITBL. This practice of patient recruitment may be criticized, but we think it is justified according to our low incidence of ITBL. Thus, it was possible to investigate 19 patients with ITBL. ITBL rate in CCR-5&#x00394;32 patients was virtually equal to the one in CCR-5 wild-type patients. No statistically significant differences regarding ITBL or retransplantation were observed.</p><p>Why would CCR-5&#x00394;32 mutation promote the development of ITBL? CCR-5&#x00394;32 is a 32-base-pair deletion within the coding region of CCR-5, which results in a frame shift and generates a nonfunctional receptor [<xref ref-type="bibr" rid="B11">11</xref>]. Homozygous expression of CCR-5&#x00394;32 is associated with a reduced risk of asthma and with a reduced severity of rheumatoid arthritis [<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>], multiple sclerosis [<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>], and primary biliary cirrhosis (PBC) [<xref ref-type="bibr" rid="B21">21</xref>]. In other words, the nonfunctional nature of CCR-5&#x00394;32 protects the individual from autoimmune diseases where CCR-5 seems to play a central pathophysiological role. These data do not backup the theory, that immunological risk factors are dominant in the development of ITBL. Likewise, a correlation of a reduced survival rate with CCR-5&#x00394;32 would not be consistent to the literature, where CCR-5&#x00394;32 mutation is associated with an increased survival in renal [<xref ref-type="bibr" rid="B12">12</xref>], lung [<xref ref-type="bibr" rid="B13">13</xref>], heart [<xref ref-type="bibr" rid="B14">14</xref>] and islet cell transplantation [<xref ref-type="bibr" rid="B15">15</xref>]. In contrast to those findings, CCR-5&#x00394;32 is strongly associated with an increased severity of PSC [<xref ref-type="bibr" rid="B22">22</xref>]. Patients suffering from PSC have been described as carrying a higher risk for ITBL, with a reported significantly increased incidence of 15.8% to 25% [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B23">23</xref>]. Another study reported PSC as the only independent risk factor for ITBL with an incidence of 31% compared with 9% of the control group [<xref ref-type="bibr" rid="B24">24</xref>]. However, the problem of differentiation between ITBL and recurrence of PSC must be addressed. Recurrence rates of 8.6% to 25% were described for PSC after OLT [<xref ref-type="bibr" rid="B25">25</xref>&#x02013;<xref ref-type="bibr" rid="B27">27</xref>]. The diagnose of recurrence of PSC is based on cholangiographic findings of intrahepatic, hilar and/or exrahepatic strictures, duct irregularities and on the histopathological picture of fibrous cholangitis and/or fibro-obliterative lesions with or without ductopenia, biliary fibrosis, or biliary cirrhosis [<xref ref-type="bibr" rid="B28">28</xref>]. Most of these findings are neither pathognomonic for either recurrence of PSC nor ITBL [<xref ref-type="bibr" rid="B29">29</xref>]. All patients with ITBL in this study underwent percutaneous liver biopsy, and our pathologists ruled out PSC recurrence. There remains a diagnostic uncertainty.</p><p>Since two of three studies failed to show an association between ITBL and CCR-5&#x00394;32 gene polymorphism, a general recommendation for screening of OLT patients for CCR-5&#x00394;32 does not seem to be justified.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guichelaar</surname><given-names>MMJ</given-names></name><name><surname>Benson</surname><given-names>JT</given-names></name><name><surname>Malinchoc</surname><given-names>M</given-names></name><name><surname>Kroma</surname><given-names>RAF</given-names></name><name><surname>Wiesner</surname><given-names>RH</given-names></name><name><surname>Charlton</surname><given-names>MR</given-names></name></person-group><article-title>Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation</article-title><source><italic>American Journal of Transplantation</italic></source><year>2003</year><volume>3</volume><issue>7</issue><fpage>885</fpage><lpage>890</lpage><pub-id pub-id-type="pmid">12814481</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Urdazpal</surname><given-names>L</given-names></name><name><surname>Gores</surname><given-names>GJ</given-names></name><name><surname>Ward</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Ischemic-type biliary complications after orthotopic liver transplantation</article-title><source><italic>Hepatology</italic></source><year>1992</year><volume>16</volume><issue>1</issue><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">1618482</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langrehr</surname><given-names>JM</given-names></name><name><surname>Schneller</surname><given-names>A</given-names></name><name><surname>Neuhaus</surname><given-names>R</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Hintze</surname><given-names>R</given-names></name><name><surname>Neuhaus</surname><given-names>P</given-names></name></person-group><article-title>Etiologic factors and incidence of ischemic type biliary lesions (ITBL) after liver transplantation</article-title><source><italic>Langenbecks Archiv f&#x000fc;r Chirurgie</italic></source><year>1998</year><volume>115</volume><fpage>1560</fpage><lpage>1562</lpage></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Stratta</surname><given-names>RJ</given-names></name><name><surname>Langnas</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Diffuse biliary tract injury after orthotopic liver transplantation</article-title><source><italic>American Journal of Surgery</italic></source><year>1992</year><volume>164</volume><issue>5</issue><fpage>536</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">1443384</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Nishida</surname><given-names>S</given-names></name><name><surname>Neff</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Intrahepatic biliary strictures without hepatic artery thrombosis after liver transplantation: an analysis of 1,113 liver transplantations at a single center</article-title><source><italic>Transplantation</italic></source><year>2005</year><volume>79</volume><issue>4</issue><fpage>427</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">15729168</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moench</surname><given-names>C</given-names></name><name><surname>Uhrig</surname><given-names>A</given-names></name><name><surname>Lohse</surname><given-names>AW</given-names></name><name><surname>Otto</surname><given-names>G</given-names></name></person-group><article-title>CC chemokine receptor 5&#x00394;32 polymorphism&#x02014;a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation</article-title><source><italic>Liver Transplantation</italic></source><year>2004</year><volume>10</volume><issue>3</issue><fpage>434</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">15004773</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Urdazpal</surname><given-names>L</given-names></name><name><surname>Gores</surname><given-names>GJ</given-names></name><name><surname>Ward</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Clinical outcome of ischemic-type biliary complications after liver transplantation</article-title><source><italic>Transplantation Proceedings</italic></source><year>1993</year><volume>25</volume><issue>1, part 2</issue><fpage>1107</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">8442058</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Urdazpal</surname><given-names>L</given-names></name><name><surname>Gores</surname><given-names>GJ</given-names></name><name><surname>Ward</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation</article-title><source><italic>Hepatology</italic></source><year>1993</year><volume>17</volume><issue>4</issue><fpage>605</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">8477965</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer-Maas</surname><given-names>L</given-names></name><name><surname>Schneppenheim</surname><given-names>R</given-names></name><name><surname>Oyen</surname><given-names>F</given-names></name><etal/></person-group><article-title>Analysis of the CC chemokine receptor 5&#x00394;32 polymorphism in pediatric liver transplant recipients</article-title><source><italic>Pediatric Transplantation</italic></source><year>2008</year><volume>12</volume><issue>7</issue><fpage>769</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">18194353</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabeti</surname><given-names>PC</given-names></name><name><surname>Walsh</surname><given-names>E</given-names></name><name><surname>Schaffner</surname><given-names>SF</given-names></name><etal/></person-group><article-title>The case for selection at CCR5-&#x00394;32</article-title><source><italic>PLoS Biology</italic></source><year>2005</year><volume>3</volume><issue>11</issue><fpage>p. e378</fpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Paxton</surname><given-names>WA</given-names></name><name><surname>Kassam</surname><given-names>N</given-names></name><etal/></person-group><article-title>CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro</article-title><source><italic>Journal of Experimental Medicine</italic></source><year>1997</year><volume>185</volume><issue>9</issue><fpage>1681</fpage><lpage>1691</lpage><pub-id pub-id-type="pmid">9151905</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischereder</surname><given-names>M</given-names></name><name><surname>Luckow</surname><given-names>B</given-names></name><name><surname>Hocher</surname><given-names>B</given-names></name><etal/></person-group><article-title>CC chemokine receptor 5 and renal-transplant survival</article-title><source><italic>The Lancet</italic></source><year>2001</year><volume>357</volume><issue>9270</issue><fpage>1758</fpage><lpage>1761</lpage></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belperio</surname><given-names>JA</given-names></name><name><surname>Burdick</surname><given-names>MD</given-names></name><name><surname>Keane</surname><given-names>MP</given-names></name><etal/></person-group><article-title>The role of the CC chemokine, RANTES, in acute lung allograft rejection</article-title><source><italic>The Journal of Immunology</italic></source><year>2000</year><volume>165</volume><issue>1</issue><fpage>461</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">10861085</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fildes</surname><given-names>JE</given-names></name><name><surname>Walker</surname><given-names>AH</given-names></name><name><surname>Howlett</surname><given-names>R</given-names></name><etal/></person-group><article-title>Donor CCR5 &#x00394;32 polymorphism and outcome following cardiac transplantation</article-title><source><italic>Transplantation Proceedings</italic></source><year>2005</year><volume>37</volume><issue>5</issue><fpage>2247</fpage><lpage>2249</lpage><pub-id pub-id-type="pmid">15964389</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdi</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>RN</given-names></name><name><surname>Makhlouf</surname><given-names>L</given-names></name><etal/></person-group><article-title>The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection</article-title><source><italic>Diabetes</italic></source><year>2002</year><volume>51</volume><issue>8</issue><fpage>2489</fpage><lpage>2495</lpage><pub-id pub-id-type="pmid">12145162</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinson</surname><given-names>JJ</given-names></name><name><surname>Chapman</surname><given-names>NH</given-names></name><name><surname>Rees</surname><given-names>DC</given-names></name><name><surname>Liu</surname><given-names>Y-T</given-names></name><name><surname>Clegg</surname><given-names>JB</given-names></name></person-group><article-title>Global distribution of the CCR5 gene 32-basepair deletion</article-title><source><italic>Nature Genetics</italic></source><year>1997</year><volume>16</volume><issue>1</issue><fpage>100</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">9140404</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garred</surname><given-names>P</given-names></name><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><etal/></person-group><article-title>CC chemokine receptor 5 polymorphism in rheumatoid arthritis</article-title><source><italic>Journal of Rheumatology</italic></source><year>1998</year><volume>25</volume><issue>8</issue><fpage>1462</fpage><lpage>1465</lpage><pub-id pub-id-type="pmid">9712084</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pokorny</surname><given-names>V</given-names></name><name><surname>McQueen</surname><given-names>F</given-names></name><name><surname>Yeoman</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis</article-title><source><italic>Annals of the Rheumatic Diseases</italic></source><year>2005</year><volume>64</volume><issue>3</issue><fpage>487</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">15331395</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulkkinen</surname><given-names>K</given-names></name><name><surname>Luomala</surname><given-names>M</given-names></name><name><surname>Kuusisto</surname><given-names>H</given-names></name><etal/></person-group><article-title>Increase in CCR5 &#x00394;32/&#x00394;32 genotype in multiple sclerosis</article-title><source><italic>Acta Neurologica Scandinavica</italic></source><year>2004</year><volume>109</volume><issue>5</issue><fpage>342</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">15080861</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kantarci</surname><given-names>OH</given-names></name><name><surname>Morales</surname><given-names>Y</given-names></name><name><surname>Ziemer</surname><given-names>PA</given-names></name><etal/></person-group><article-title>CCR5&#x00394;32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis</article-title><source><italic>Journal of Neuroimmunology</italic></source><year>2005</year><volume>169</volume><issue>1-2</issue><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">16182378</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>DEJ</given-names></name><name><surname>Donaldson</surname><given-names>PT</given-names></name></person-group><article-title>Genetic factors in the pathogenesis of primary biliary cirrhosis</article-title><source><italic>Clinics in Liver Disease</italic></source><year>2003</year><volume>7</volume><issue>4</issue><fpage>841</fpage><lpage>864</lpage><pub-id pub-id-type="pmid">14594133</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eri</surname><given-names>R</given-names></name><name><surname>Jonsson</surname><given-names>JR</given-names></name><name><surname>Pandeya</surname><given-names>N</given-names></name><etal/></person-group><article-title>CCR5-&#x00394;32 mutation is strongly associated with primary sclerosing cholangitis</article-title><source><italic>Genes and Immunity</italic></source><year>2004</year><volume>5</volume><issue>6</issue><fpage>444</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">15215889</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liermann Garcia</surname><given-names>RF</given-names></name><name><surname>Evangelista Garcia</surname><given-names>C</given-names></name><name><surname>McMaster</surname><given-names>P</given-names></name><name><surname>Neuberger</surname><given-names>J</given-names></name></person-group><article-title>Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center</article-title><source><italic>Hepatology</italic></source><year>2001</year><volume>33</volume><issue>1</issue><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">11124816</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feller</surname><given-names>RB</given-names></name><name><surname>Waugh</surname><given-names>RC</given-names></name><name><surname>Selby</surname><given-names>WS</given-names></name><name><surname>Dolan</surname><given-names>PM</given-names></name><name><surname>Sheil</surname><given-names>AGR</given-names></name><name><surname>Mccaughan</surname><given-names>GW</given-names></name></person-group><article-title>Biliary strictures after liver transplantation: clinical picture, correlates and outcomes</article-title><source><italic>Journal of Gastroenterology and Hepatology</italic></source><year>1996</year><volume>11</volume><issue>1</issue><fpage>21</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">8672737</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narumi</surname><given-names>S</given-names></name><name><surname>Roberts</surname><given-names>JP</given-names></name><name><surname>Emond</surname><given-names>JC</given-names></name><name><surname>Lake</surname><given-names>J</given-names></name><name><surname>Ascher</surname><given-names>NL</given-names></name></person-group><article-title>Liver transplantation for sclerosing cholangitis</article-title><source><italic>Hepatology</italic></source><year>1995</year><volume>22</volume><issue>2</issue><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">7635412</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>R</given-names></name><name><surname>Campbell</surname><given-names>WL</given-names></name><name><surname>Zajko</surname><given-names>AB</given-names></name><name><surname>Baron</surname><given-names>RL</given-names></name></person-group><article-title>Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease</article-title><source><italic>American Journal of Roentgenology</italic></source><year>1996</year><volume>166</volume><issue>5</issue><fpage>1109</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">8615253</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graziadei</surname><given-names>IW</given-names></name><name><surname>Wiesner</surname><given-names>RH</given-names></name><name><surname>Batts</surname><given-names>KP</given-names></name><etal/></person-group><article-title>Recurrence of primary sclerosing cholangitis following liver transplantation</article-title><source><italic>Hepatology</italic></source><year>1999</year><volume>29</volume><issue>4</issue><fpage>1050</fpage><lpage>1056</lpage><pub-id pub-id-type="pmid">10094945</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeyarajah</surname><given-names>DR</given-names></name><name><surname>Netto</surname><given-names>GJ</given-names></name><name><surname>Lee</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process?</article-title><source><italic>Transplantation</italic></source><year>1998</year><volume>66</volume><issue>10</issue><fpage>1300</fpage><lpage>1306</lpage><pub-id pub-id-type="pmid">9846512</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Ari</surname><given-names>Z</given-names></name><name><surname>Pappo</surname><given-names>O</given-names></name><name><surname>Mor</surname><given-names>E</given-names></name></person-group><article-title>Intrahepatic cholestasis after liver transplantation</article-title><source><italic>Liver Transplantation</italic></source><year>2003</year><volume>9</volume><issue>10</issue><fpage>1005</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">14526393</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Intrahepatic presentation of ischemic-type biliary lesion six months after hepatic transplantation for chronic hepatitis B-associated liver cirrhosis. The patient's hepatic artery is patent, and there is no other known cause for the destruction of the intrahepatic biliary tract.</p></caption><graphic xlink:href="JTRAN2009-436515.001"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Recipient characteristics. MELD: model for end-stage liver disease; CPS: Child-Pugh score; BG: recipients blood group; wt/wt: wild-type CCR-5; wt/&#x00394;32: heterozygous CCR-5&#x00394;32; &#x00394;32/&#x00394;32: homozygous CCR-5&#x00394;32; CMV: cytomegalovirus; OKT-3: monoclonal murine anti-CD-3 antibody.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="5" rowspan="1"> Recipient characteristics </th></tr><tr><th align="left" rowspan="1" colspan="1"> Variables </th><th align="center" rowspan="1" colspan="1"> wt/wt </th><th align="center" rowspan="1" colspan="1"> wt/&#x00394;32</th><th align="center" rowspan="1" colspan="1">&#x00394;32/&#x00394;32</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>n</italic> (169)</td><td align="center" rowspan="1" colspan="1">134 (79.3%)</td><td align="center" rowspan="1" colspan="1">33 (19.5%)</td><td align="center" rowspan="1" colspan="1">2 (1.2%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Recipient gender</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;Male</td><td align="center" rowspan="1" colspan="1">89 (66.4%)</td><td align="center" rowspan="1" colspan="1">22 (66.7%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1">.137</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;Female</td><td align="center" rowspan="1" colspan="1">45 (33.6%)</td><td align="center" rowspan="1" colspan="1">11 (33.3%)</td><td align="center" rowspan="1" colspan="1">2 (100%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean recipient age (years)</td><td align="center" rowspan="1" colspan="1">50.2 &#x000b1; 10.3</td><td align="center" rowspan="1" colspan="1">49.8 &#x000b1; 9.9</td><td align="center" rowspan="1" colspan="1">47.5 &#x000b1; 17.7</td><td align="center" rowspan="1" colspan="1">.443</td></tr><tr><td align="left" rowspan="1" colspan="1">MELD Score (mean &#x000b1; SD)</td><td align="center" rowspan="1" colspan="1">17.2 &#x000b1; 8.7</td><td align="center" rowspan="1" colspan="1">17.9 &#x000b1; 9</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1">.960</td></tr><tr><td align="left" rowspan="1" colspan="1">CPS A</td><td align="center" rowspan="1" colspan="1">13 (11.8%)</td><td align="center" rowspan="1" colspan="1">4 (16%)</td><td align="center" rowspan="1" colspan="1">1 (50%)</td><td align="center" rowspan="1" colspan="1">.487</td></tr><tr><td align="left" rowspan="1" colspan="1">CPS B</td><td align="center" rowspan="1" colspan="1">60 (54.5%)</td><td align="center" rowspan="1" colspan="1">13 (52%)</td><td align="center" rowspan="1" colspan="1">1 (50%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CPS C</td><td align="center" rowspan="1" colspan="1">37 (33.7%)</td><td align="center" rowspan="1" colspan="1">8 (32%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BG A</td><td align="center" rowspan="1" colspan="1">52 (39.1%)</td><td align="center" rowspan="1" colspan="1">10 (30.3%)</td><td align="center" rowspan="1" colspan="1">1 (50%)</td><td align="center" rowspan="1" colspan="1">.823</td></tr><tr><td align="left" rowspan="1" colspan="1">BG B</td><td align="center" rowspan="1" colspan="1">19 (14.3%)</td><td align="center" rowspan="1" colspan="1">4 (12.1%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BG AB</td><td align="center" rowspan="1" colspan="1">15 (11.3%)</td><td align="center" rowspan="1" colspan="1">3 (9.1%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BG O</td><td align="center" rowspan="1" colspan="1">47 (35.3%)</td><td align="center" rowspan="1" colspan="1">16 (48.5%)</td><td align="center" rowspan="1" colspan="1">1 (50%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hepatitis B-related cirrhosis</td><td align="center" rowspan="1" colspan="1">16 (11.9%)</td><td align="center" rowspan="1" colspan="1">3 (9.1%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1">.918</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatitis C-related cirrhosis</td><td align="center" rowspan="1" colspan="1">21 (15.7%)</td><td align="center" rowspan="1" colspan="1">6 (18.2%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hepatocellular carcinoma</td><td align="center" rowspan="1" colspan="1">19 (14.2%)</td><td align="center" rowspan="1" colspan="1">4 (12.1%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Primary biliary cirrhosis</td><td align="center" rowspan="1" colspan="1">6 (4.5%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1">2 (100%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Primary sclerosing cholangitis</td><td align="center" rowspan="1" colspan="1">4 (3%)</td><td align="center" rowspan="1" colspan="1">2 (6.1%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Acute liver failure</td><td align="center" rowspan="1" colspan="1">4 (3%)</td><td align="center" rowspan="1" colspan="1">3 (9.1%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Autoimmune hepatitis</td><td align="center" rowspan="1" colspan="1">2 (1.5%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Metabolic liver diseases</td><td align="center" rowspan="1" colspan="1">2 (1.5%)</td><td align="center" rowspan="1" colspan="1">3 (9.1%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Alcohol-induced cirrhosis</td><td align="center" rowspan="1" colspan="1">41 (30.6%)</td><td align="center" rowspan="1" colspan="1">9 (27.3%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Retransplantation</td><td align="center" rowspan="1" colspan="1">4 (3%)</td><td align="center" rowspan="1" colspan="1">1 (3%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Others</td><td align="center" rowspan="1" colspan="1">15 (11.2%)</td><td align="center" rowspan="1" colspan="1">2 (6.1%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cold ischemic time (minutes)</td><td align="center" rowspan="1" colspan="1">533 &#x000b1; 144</td><td align="center" rowspan="1" colspan="1">582 &#x000b1; 202</td><td align="center" rowspan="1" colspan="1">633</td><td align="center" rowspan="1" colspan="1">.806</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial Immunosuppression</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;Tacrolimus</td><td align="center" rowspan="1" colspan="1">110 (82.6%)</td><td align="center" rowspan="1" colspan="1">28 (84.8%)</td><td align="center" rowspan="1" colspan="1">2 (100%)</td><td align="center" rowspan="1" colspan="1">.824</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;Cyclosporine A</td><td align="center" rowspan="1" colspan="1">23 (17.2%)</td><td align="center" rowspan="1" colspan="1">4 (12.1%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;others</td><td align="center" rowspan="1" colspan="1">1 (0.7%)</td><td align="center" rowspan="1" colspan="1">1 (3.0%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HLA match</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;0 match</td><td align="center" rowspan="1" colspan="1">24 (26.4%)</td><td align="center" rowspan="1" colspan="1">6 (27.3%)</td><td align="center" rowspan="1" colspan="1">2 (100%)</td><td align="center" rowspan="1" colspan="1">.448</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;1 match</td><td align="center" rowspan="1" colspan="1">40 (44.0%)</td><td align="center" rowspan="1" colspan="1">8 (36.4%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;2 matches</td><td align="center" rowspan="1" colspan="1">21 (23.1%)</td><td align="center" rowspan="1" colspan="1">5 (19.2%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;3 matches</td><td align="center" rowspan="1" colspan="1">5 (5.5%)</td><td align="center" rowspan="1" colspan="1">2 (9.1%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;4&#x02013;6 matches</td><td align="center" rowspan="1" colspan="1">1 (1.1%)</td><td align="center" rowspan="1" colspan="1">1 (4.5%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CMV Infection</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;postitve</td><td align="center" rowspan="1" colspan="1">43 (32.1%)</td><td align="center" rowspan="1" colspan="1">12 (36.4%)</td><td align="center" rowspan="1" colspan="1">2 (100%)</td><td align="center" rowspan="1" colspan="1">.117</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;negative</td><td align="center" rowspan="1" colspan="1">28 (20.9%)</td><td align="center" rowspan="1" colspan="1">2 (6.1%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;unknown</td><td align="center" rowspan="1" colspan="1">63 (47.0%)</td><td align="center" rowspan="1" colspan="1">19 (57.6%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Donor characteristics. ICU: intensive care unit; wt/wt: wild-type CCR-5; wt/&#x00394;32: heterozygous CCR-5&#x00394;32; &#x00394;32/&#x00394;32: homozygous CCR-5&#x00394;32.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="5" rowspan="1"> Donor characteristics </th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"> wt </th><th align="center" rowspan="1" colspan="1"> wt/&#x00394;32</th><th align="center" rowspan="1" colspan="1">&#x00394;32/&#x00394;32</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value </th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Donor age (years)</td><td align="center" rowspan="1" colspan="1">46.5 &#x000b1; 17.2</td><td align="center" rowspan="1" colspan="1">48.5 &#x000b1; 16.5</td><td align="center" rowspan="1" colspan="1">35.7 &#x000b1; 11.2</td><td align="center" rowspan="1" colspan="1">.663</td></tr><tr><td align="left" rowspan="1" colspan="1">Donor gender</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;Male</td><td align="center" rowspan="1" colspan="1">76 (56.7%)</td><td align="center" rowspan="1" colspan="1">20 (60.6%)</td><td align="center" rowspan="1" colspan="1">1 (50%)</td><td align="center" rowspan="1" colspan="1">.901</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;Female</td><td align="center" rowspan="1" colspan="1">58 (43.3%)</td><td align="center" rowspan="1" colspan="1">13 (39.4%)</td><td align="center" rowspan="1" colspan="1">1 (50%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean donor serum Na<sup>+</sup> (mmol/L)</td><td align="center" rowspan="1" colspan="1">146.9 &#x000b1; 8.4</td><td align="center" rowspan="1" colspan="1">147.7 &#x000b1; 7.9</td><td align="center" rowspan="1" colspan="1">155,5 &#x000b1; 27.5</td><td align="center" rowspan="1" colspan="1">.552</td></tr><tr><td align="left" rowspan="1" colspan="1">Cause of brain death</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;Subarachnoidal bleeding</td><td align="center" rowspan="1" colspan="1">75 (56%)</td><td align="center" rowspan="1" colspan="1">16 (48.5%)</td><td align="center" rowspan="1" colspan="1">1 (50%)</td><td align="center" rowspan="1" colspan="1">.866</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;Trauma</td><td align="center" rowspan="1" colspan="1">31 (23.1%)</td><td align="center" rowspan="1" colspan="1">8 (24.2%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;Intracerebral bleeding</td><td align="center" rowspan="1" colspan="1">1 (0.7%)</td><td align="center" rowspan="1" colspan="1">1 (0.6%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;Hypoxia</td><td align="center" rowspan="1" colspan="1">3 (2.2%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;Brain tumor</td><td align="center" rowspan="1" colspan="1">1 (0.7%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;Cardiac infarction</td><td align="center" rowspan="1" colspan="1">1 (0.7%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;Cerebral infarction</td><td align="center" rowspan="1" colspan="1">10 (7.5%)</td><td align="center" rowspan="1" colspan="1">3 (9.1%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02003;others</td><td align="center" rowspan="1" colspan="1">12 (9%)</td><td align="center" rowspan="1" colspan="1">5 (15.2%)</td><td align="center" rowspan="1" colspan="1">1 (50%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stay on the ICU prior to Organ harvesting (days)</td><td align="center" rowspan="1" colspan="1">4.3 &#x000b1; 4.7</td><td align="center" rowspan="1" colspan="1">4.7 &#x000b1; 3.8</td><td align="center" rowspan="1" colspan="1">7.0</td><td align="center" rowspan="1" colspan="1">.564</td></tr></tbody></table></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>Events after transplantation. wt/wt: wild type CCR-5; wt/&#x00394;32: heterozygous CCR-5&#x00394;32; &#x00394;32/&#x00394;32: homozygous CCR-5&#x00394;32; ITBL: ischemic-type biliary lesion; Re-OLT: retransplantation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="5" rowspan="1"> Incidence of ITBL or Re-transplantation </th></tr><tr><th align="left" rowspan="1" colspan="1"> Events </th><th align="center" rowspan="1" colspan="1"> wt/wt </th><th align="center" rowspan="1" colspan="1"> wt/&#x00394;32</th><th align="center" rowspan="1" colspan="1">&#x00394;32/&#x00394;32</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value </th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>n</italic></td><td align="center" rowspan="1" colspan="1">134</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No ITBL</td><td align="center" rowspan="1" colspan="1">119 (88.8%)</td><td align="center" rowspan="1" colspan="1">29 (87.9%)</td><td align="center" rowspan="1" colspan="1">2(100%)</td><td align="center" rowspan="1" colspan="1">.870</td></tr><tr><td align="left" rowspan="1" colspan="1">ITBL</td><td align="center" rowspan="1" colspan="1">15 (11.2%)</td><td align="center" rowspan="1" colspan="1">4 (12.1%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No Re-OLTx</td><td align="center" rowspan="1" colspan="1">130 (97%)</td><td align="center" rowspan="1" colspan="1">32 (97%)</td><td align="center" rowspan="1" colspan="1">2 (100%)</td><td align="center" rowspan="1" colspan="1">.970</td></tr><tr><td align="left" rowspan="1" colspan="1">Re-OLTx</td><td align="center" rowspan="1" colspan="1">3(3%)</td><td align="center" rowspan="1" colspan="1">1 (3%)</td><td align="center" rowspan="1" colspan="1">&#x02014; </td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></floats-group></article>